Short interest for TG Therapeutics gives investors a sense of the degree to which investors are betting on the decline of TG Therapeutics's stock. Short interest data is updated every two weeks.

TG Therapeutics Stock (NASDAQ:TGTX), Short Interest Report

TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

amd shutter

News

Intraday Update

Markets

Movers

AKAN

ASTE

ATEN

CDNA

CETX

CHEF

CNDT

CTMX

CVRX

DBRG

DPSI

GETR

GRMN

IMCC

LGHL

LMND

MNDR

NARI

NCLH

NYCB

PALI

PINS

PLTN

POAI

POWL

PSNY

RCKY

ROOT

SBUX

SITE

SMCI

SOBR

SRDX

STGW

SWKS

TECH

TGTX

TMDX

UFPT

XTIA

Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Image 4

AMCR

AXTA

DOCN

LIVN

UTHR

Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday

Penny Stocks

Small Cap

Trading Ideas

ACMR

ADIL

ALHC

ANTE

APLT

BAND

BETS

BIDU

BMBL

BYND

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CNXC

COCO

CRGE

EBAY

EDIT

FLYW

GTLS

IFBD

IMNN

INGN

IXHL

KITT

LAZR

LFST

MSTR

MVLA

NRDY

NVAX

OCEA

OGEN

PAYO

PGNY

QRTEA

RBOT

RVLV

RXRX

SMXT

URBN

VANI

VIPS

VTNR

VTVT

VTYX

Shares of  Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

TG Therapeutics Inc

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on TG Therapeutics (TGTX – Research Report). Th...

Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)

Mayank Mamtani, an analyst from B.Riley Financial, reiterated the Buy rating on TG Therapeutics (TGTX – Research Report). The associated price targ...

Briumvi's Market Share Growth and TG Therapeutics' Strong Financial Outlook Justify Buy Rating

TG Therapeutics GAAP EPS of -$0.07 misses by $0.03, revenue of $63.47M beats by $8.86M

TG Therapeutics jumps as Q1 Briumvi sales top guidance

TG Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) is up 30% on Wednesday even though it reported a wider-than-expected per-share loss for its fiscal first quarter.

TG Therapeutics stock just rallied 30%: what happened?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TG Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tgtx-stock-quote/"><strong>TGTX</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>TG Therapeutics reported earnings per share of -7 cents. This was below the analyst estimate for EPS of -4 cents.</li><li>The company reported revenue of $63.47 million.</li><li>This was 16.30% better than the analyst estimate for revenue of $54.58 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/tgtx-stock-earnings-tg-therapeutics-for-q1-of-2024/">TGTX Stock Earnings: TG Therapeutics Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TGTX Stock Earnings: TG Therapeutics Misses EPS, Beats Revenue for Q1 2024

In a report released today, Corinne Johnson from Goldman Sachs maintained a Hold rating on TG Therapeutics (TGTX – Research Report), with a price t...

Hold Rating on TG Therapeutics Amidst Strong Briumvi Launch and Competitive Market Pressures

TG Therapeutics (TGTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Alec Stranahan f...

Sell Rating on TG Therapeutics: Caution Amid Competitive Threats and Decelerating Prescription Growth

TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript

TG Therapeutics: Less Room For Doubt About Briumvi

RHHBY

Legal

Press Releases

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

Earnings

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Health Care

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Contracts

General

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

-

-

-

-

-

-

-

-

-

-

-

-

-

-

TG Therapeutics Stock (NASDAQ:TGTX), Short Interest Report

People Also Watch